FDA Grants Breakthrough Therapy Status to Johnson & Johnson’s Nipocalimab for HDFN Treatment
SPRING HOUSE, PA — Johnson & Johnson recently announced that its investigational drug, nipocalimab, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). The designation …
FDA Grants Breakthrough Therapy Status to Johnson & Johnson’s Nipocalimab for HDFN Treatment Read More